Global leishmaniasis surveillance updates 2023: 3 years of the NTD road map

Overview

Leishmaniasis continues to be a major health problem in 4 eco-epidemiological regions of the world: the Americas, East Africa, North Africa and West and South-East Asia.

This report on global leishmaniasis surveillance follows those published in 2016–2023.2–6 Six indicators of leishmaniasis are publicly available from the Global Health Observatory (GHO).7 In addition to the GHO, country profiles with up to 30 indicators are published, with detailed data received from 45 Member States.

The aims of this report are to update the description of the GHO leishmaniasis indicators reported by Member States to WHO up to 2023, to describe specific indicators of gender and age distribution, relapse, treatment for cutaneous leishmaniasis (CL), visceral leishmaniasis (VL) and VL treatment outcomes, VL case fatality rates (CFRs) and the burden of post kala-azar dermal leishmaniasis (PKDL). The report also contains a brief section on HIV–VL coinfection, the kala-azar elimination programme in South-East Asia and the VL elimination initiative in eastern Africa. Leishmaniasis fact sheet. Geneva: World Health Organ.